Missense or truncation mutations in TYRO3 were also identified in 3 of 23 samples from patients with CML who developed resistance to BCR-ABL inhibitors while on therapy and did not have a resistance conferring mutation in BCR-ABL itself, although the significance of this finding is also unknown [80]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.